Minimal disease activity as a treatment target in psoriatic arthritis: A review of the literature

TY - JOUR

T1 - Minimal disease activity as a treatment target in psoriatic arthritis

T2 - A review of the literature

AU - Gossec, Laure

AU - McGonagle, Dennis

AU - Korotaeva, Tatiana

AU - Lubrano, Ennio

AU - De Miguel, Eugenio

AU - Østergaard, Mikkel

AU - Behrens, Frank

PY - 2018

Y1 - 2018

N2 - As in other inflammatory rheumatic diseases, the objective of psoriatic arthritis (PsA) treatment is the achievement of a defined target. Recent recommendations propose aiming for remission or low disease activity; however, a consensual definition of remission is lacking. A state of minimal disease activity (MDA) has been established and is defined by low activity assessed by tender/swollen joint counts, tender entheseal points, Psoriasis Area and Severity Index or body surface area, patient pain and global activity visual analog scale, and functional evaluation by Health Assessment Questionnaire. Since its development, MDA has been used increasingly in studies and clinical trials. In this article, the potential use of MDA as a treatment target in PsA is reviewed. The frequencies of MDA achievement with biologic disease-modifying antirheumatic drugs are summarized based on data from registries, observational studies, and clinical trials. Predictors and the prognostic effect of attaining MDA are also evaluated.

AB - As in other inflammatory rheumatic diseases, the objective of psoriatic arthritis (PsA) treatment is the achievement of a defined target. Recent recommendations propose aiming for remission or low disease activity; however, a consensual definition of remission is lacking. A state of minimal disease activity (MDA) has been established and is defined by low activity assessed by tender/swollen joint counts, tender entheseal points, Psoriasis Area and Severity Index or body surface area, patient pain and global activity visual analog scale, and functional evaluation by Health Assessment Questionnaire. Since its development, MDA has been used increasingly in studies and clinical trials. In this article, the potential use of MDA as a treatment target in PsA is reviewed. The frequencies of MDA achievement with biologic disease-modifying antirheumatic drugs are summarized based on data from registries, observational studies, and clinical trials. Predictors and the prognostic effect of attaining MDA are also evaluated.

KW - Biologic therapy

KW - Disease activity

KW - Psoriatic arthritis

KW - Remission

U2 - 10.3899/jrheum.170449

DO - 10.3899/jrheum.170449

M3 - Review

C2 - 29142032

AN - SCOPUS:85040083737

SN - 0315-162X

VL - 45

SP - 6

EP - 13

JO - Journal of Rheumatology

JF - Journal of Rheumatology

IS - 1

ER -